Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Analysts' Corner
NEW YORK, October 23, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), pSivida Corp. (NASDAQ: PSDV), Momenta Pharmaceuticals Inc. (NASDAQ: MNTA) and Impax Laboratories Inc. (NASDAQ: IPXL). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Alexion Pharmaceuticals, Inc. Research Report
On October 16, 2013, Alexion Pharmaceuticals (Alexion) announced that its researchers are scheduled to present data from clinical studies of Soliris (eculizumab) in patients with atypical hemolytic uremic syndrome (aHUS), at the annual meeting of the American Society of Nephrology (ASN), to be held from November 5, 2013 to November 10, 2013, in Atlanta, Georgia. The Company informed that that aHUS is a genetic, life-long, ultra-rare disease associated with vital organ failure and premature death. Alexion stated that the presentation will include: results from a prospective clinical trial of Soliris in pediatric patients with aHUS, following the published results of a retrospective study in pediatric patients with aHUS; results from an expanded adult population, representing the largest prospective trial of Soliris in adult patients with aHUS; and three-year follow-up data from two pivotal Phase 2 extension studies that highlight the long-term benefits of Soliris therapy in patients with aHUS. The Full Research Report on Alexion Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/4619_ALXN]
Pacira Pharmaceuticals Inc. Research Report
On October 17, 2013, Pacira Pharmaceuticals Inc. (Pacira) announced that it will release its Q3 2013 financial results before the market opens on October 31, 2013. The Company stated that its management team will host a conference call to discuss its financial results along with recent and upcoming developments on the same day at 9:00 a.m. ET. The Company informed that a live, listen-only webcast of the call will be available at the "Investors & Media" section of the Company's website. Pacira added that the replay of the call for two weeks, approximately two hours following the call will also be accessible at the same location. The Full Research Report on Pacira Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/c0aa_PCRX]
pSivida Corp. Research Report
On October 18, 2013, pSivida Corp. (pSivida) announced that its licensee Alimera Sciences, Inc. has received a Complete Response Letter (CRL) for the New Drug Application (NDA) for ILUVIEN from the U.S. Food and Drug Administration (FDA). pSivida informed that the FDA stated that its NDA could not be approved in its present form, due to concerns regarding the benefit to risk and safety profiles of ILUVIEN. The Company informed that in order to address the clinical and statistical deficiencies identified, FDA indicated that results from a new clinical trial would need to be submitted, along with at least 12 months of follow-up for all enrolled patients. Paul Ashton, PhD, President and CEO of pSivida stated, "We are extremely disappointed by the FDA's decision not to approve ILUVIEN at this time. However, we are pleased that Alimera plans to continue to work with the FDA, through the advisory committee, to determine whether there is a path forward in the U.S. for ILUVIEN, and that Alimera believes it is well positioned for growth in Europe, irrespective of the U.S. outcome, based on current traction in the countries in which ILUVIEN has already been approved, coupled with the continued pursuit of further country approvals." The Full Research Report on pSivida Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/d4eb_PSDV]
Momenta Pharmaceuticals Inc. Research Report
On October 15, 2013, Momenta Pharmaceuticals Inc. (Momenta) announced that it will release its Q3 2013 financial results on November 5, 2013 before the US financial markets open. The Company informed that its management will host a conference call on the same day at 10:00 a.m. EDT to discuss the results and provide an update on the Company. Momenta added that a live webcast of the call can be accessed through the "Investors" section of its website, and an archived version of the webcast will be available on the website approximately two hours following the call. The Full Research Report on Momenta Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/c334_MNTA]
Impax Laboratories Inc. Research Report
On October 8, 2013, Impax Laboratories Inc. (Impax) announced that it will release its Q3 2013 financial results on November 4, 2013, after the closing of US financial markets. Impax informed that it will host a conference call and live webcast on the same day at 4:30 p.m., ET. The Company stated that the financial results and live webcast will be available through the Investor Relations section of the Company's website. The Full Research Report on Impax Laboratories Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/4c54_IPXL]
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
©2012 PR Newswire. All Rights Reserved.